Memantine Grindeks (Memantine Hydrochloride)

Memantine Grindeks is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease.

• Alzheimer’s disease: improves cognition and functional abilities in patients with moderate to severe disease

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx that occurs during pathological glutamate stimulation, thereby limiting excitotoxic neuronal injury while preserving normal synaptic transmission.

Adverse reactions may occur with memantine therapy and are reported with varying frequency.

Common Side Effects

• Dizziness: mild to moderate vertigo or light‑headedness
• Headache: transient cranial pain
• Constipation: reduced bowel movements
• Confusion: transient disorientation or impaired concentration
• Hypertension: mild increase in blood pressure
• Fatigue: feeling unusually tired

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring medical attention
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Cardiac arrhythmias: irregular heart rhythm events
• Hallucinations: visual or auditory disturbances
• Anaphylaxis: acute allergic reaction with respiratory compromise

Memantine Grindeks should be used with attention to patient‑specific factors and storage requirements.

• Renal impairment: monitor renal function and adjust therapy as needed
• Hepatic impairment: use with caution; monitor liver enzymes
• History of seizures: observe for increased seizure activity
• Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity
• Pregnancy and lactation: safety not established; weigh benefits against potential risks
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight

Potential drug interactions with memantine should be reviewed before therapy.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity
• Ketamine: combined NMDA blockade can cause severe central nervous system depression
• Other memantine‑containing products: risk of overdose and heightened adverse effects

Moderate Interactions (Monitor Closely)

• Anticholinesterases (e.g., donepezil, rivastigmine): may increase dizziness or confusion
• Diuretics (e.g., furosemide): may raise memantine plasma concentrations
• CNS depressants (e.g., benzodiazepines): may enhance sedation and impair coordination